BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
BeyondSpring Inc., a clinical-stage biopharmaceutical company, announced a strategic leadership transition effective July 1, 2026, to focus on executing its confirmatory DUBLIN-4 Phase 3 trial for Plinabulin in non-squamous EGFR wild-type NSCLC patients. The company appoints Min Qiu as CEO with a mandate to complete DUBLIN-4, extend Plinabulin's sc…